Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSI) Depreciation & Amortization (CF) (2022 - 2025)

TriSalus Life Sciences (TLSI) has 4 years of Depreciation & Amortization (CF) data on record, last reported at $126000.0 in Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) fell 34.72% year-over-year to $126000.0; the TTM value through Dec 2025 reached $626000.0, down 15.86%, while the annual FY2025 figure was $626000.0, 15.86% down from the prior year.
  • Depreciation & Amortization (CF) reached $126000.0 in Q4 2025 per TLSI's latest filing, down from $163000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $194000.0 in Q4 2023 and bottomed at -$54000.0 in Q4 2022.
  • Average Depreciation & Amortization (CF) over 4 years is $153846.2, with a median of $172000.0 recorded in 2025.
  • Peak YoY movement for Depreciation & Amortization (CF): surged 459.26% in 2023, then crashed 34.72% in 2025.
  • A 4-year view of Depreciation & Amortization (CF) shows it stood at -$54000.0 in 2022, then soared by 459.26% to $194000.0 in 2023, then decreased by 0.52% to $193000.0 in 2024, then plummeted by 34.72% to $126000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Depreciation & Amortization (CF) were $126000.0 in Q4 2025, $163000.0 in Q3 2025, and $165000.0 in Q2 2025.